<i>Helicobacter pylori</i> Infection Detection Test – Can You Really Get Infected?

Helicobacter pylori represents a singular case among microorganisms capable of colonizing the human gastric environment. Its most distinguishing feature lies in its remarkable resilience to the highly acidic conditions prevalent in the stomach, a trait attributable to the production of a specialized enzyme—urease. Through the catalytic decomposition of urea into carbon dioxide and ammonia, the bacterium not only neutralizes the local pH, facilitating its penetration through the mucosal barrier toward epithelial cells, but also induces the dissociation of ammonia into ions, including hydroxide ions, which further damage the cellular structures of the gastric mucosa. As a microaerophilic organism, Helicobacter pylori thrives in environments with lower oxygen concentrations than those found in Earth’s atmosphere, a condition that enhances its survival in deeper mucosal layers. Its motility is enabled by specialized bipolar flagella, allowing for active movement. According to World Health Organization data, this bacterium colonizes approximately 30% of the population in highly developed countries, whereas in developing regions, this figure exceeds 60%, reaching as high as 84% among adults in Poland. Despite its widespread prevalence, only about 10% of infected individuals develop pathological changes. Routine diagnostic screening is not recommended for the general population; testing for Helicobacter pylori is conducted solely when medically indicated, such as prior to planned treatment. Available diagnostic methods are categorized into invasive procedures—requiring gastroscopy with biopsy sampling (including urease testing, histopathologic evaluation, and microbiological culture)—and non-invasive tests, which encompass stool antigen tests, serological assays, or urea breath tests.

This diagnostic assay detects *Helicobacter pylori*-specific antigens in stool samples through an immunoenzymatic reaction involving monoclonal antibodies that bind selectively to bacterial epitopes. The method demonstrates high sensitivity and is particularly advantageous for individuals with a low pretest probability of infection, as it reduces the likelihood of false-positive results compared to serological (blood-based) testing. The stool antigen test serves dual purposes: initial diagnosis of *H. pylori* infection and post-treatment verification of eradication success. A critical preparatory requirement is the discontinuation of proton pump inhibitors (PPIs, e.g., omeprazole, esomeprazole) for at least 14 days prior to specimen collection, as these medications suppress gastric acid secretion and may yield false-negative results—even in the presence of active infection. Proper sample collection involves obtaining a fresh stool specimen (approximately 1–2 cm³, comparable in size to a walnut) in a sterile, screw-capped container while adhering to aseptic techniques. The sample should be transported to the laboratory without delay; if short-term storage (up to 48 hours) is necessary, refrigeration at 2–8°C is mandatory. The approximate cost of the test ranges from $30 to $60 USD, depending on the healthcare provider and geographic location.

This assay does not represent the most reliable diagnostic tool, nor is it appropriate for assessing treatment efficacy, as its fundamental principle relies on detecting circulating antibodies—specifically immunoglobulin G (IgG) and immunoglobulin A (IgA)—targeting *Helicobacter pylori*. A critical limitation arises from the fact that detectable antibody titers may persist for up to twelve months following successful pathogen eradication, thereby compromising the test’s utility in post-treatment evaluation. Given these constraints, a pressing question emerges: what preventive strategies can be implemented to reduce the likelihood of acquiring this bacterial infection in the first place?

Regrettably, avoiding infection with this bacterium presents a significant challenge due to its high contagiousness and the ubiquity of its transmission routes. *Helicobacter pylori* spreads predominantly through oral-oral and fecal-oral pathways, meaning that infection can occur via sharing utensils, bottles, or cutlery with an infected individual, as well as through the consumption of water or food contaminated with fecal matter. An additional source of transmission may be inadequately sterilized medical equipment, particularly in facilities with substandard hygiene protocols. A critical factor facilitating infection is poor hand hygiene—bacteria can enter the body through contact with contaminated surfaces followed by touching the mouth or handling food. Furthermore, compromised immune function resulting from malnutrition, vitamin deficiencies (particularly vitamins C and E), and trace element deficiencies (such as zinc or selenium) substantially increases susceptibility to infection. It is noteworthy that the majority of infections occur during childhood, when the immune system remains immature and hygienic practices are not yet fully established. While complete elimination of risk is virtually unattainable, the most effective preventive strategy involves maintaining optimal nutritional status alongside rigorous adherence to personal and environmental hygiene standards.